ESMO 2017 | What’s the best option in the treatment of melanoma?

Michael Atkins, MD, from the Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, discusses promising data in the treatment of melanoma at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. Recent data for treatment of melanoma in the adjuvant setting shows a benefit in terms of efficacy and toxicity of nivolumab, an anti-PD1, compared to the FDA approved dose of ipilimumab. In patients with a BRAF mutation, trials investigating vemurafenib, dabrafenib, and trametinib have been shown to be beneficial in terms of progression free survival, however, this data is still relatively novel, and further observations need to be carried out